Imetelstat
Oligonucleotide Telomerase Inhibitor — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Also known as: GRN163L, imetelstat sodium, JNJ-63935937, rytelo
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Imetelstat is a drug in the Oligonucleotide Telomerase Inhibitor class catalogued in DrugCentral. It was first approved by the FDA in 2024. Its mechanism of action is classified as Oligonucleotide Telomerase Inhibitors. DrugCentral lists 1 molecular target, including TERT. Recorded indications include Low- to intermediate-1 risk myelodysplastic syndrome.
- Drug class: Oligonucleotide Telomerase Inhibitor.
- Mechanism of action: Oligonucleotide Telomerase Inhibitors.
- Molecular targets: TERT (1 listed in DrugCentral).
- Indications: Low- to intermediate-1 risk myelodysplastic syndrome.
- ATC code: L01XX80 (Other antineoplastic agents).
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (1)
- Low- to intermediate-1 risk myelodysplastic syndrome
Mechanism & targets
| Mechanism of action (MoA) | Oligonucleotide Telomerase Inhibitors |
|---|---|
| Established pharmacologic class | Oligonucleotide Telomerase Inhibitor |
Molecular targets (1)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Telomerase reverse transcriptase | TERT | inhibitor | IC50 7.25 |
Regulatory approvals (2)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 2025-03-07 | EMA | — | Geron Netherlands B.V. | Yes |
| 2024-06-06 | FDA | — | Geron | Yes |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
L01XX80 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › OTHER ANTINEOPLASTIC AGENTS › Other antineoplastic agents |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Cytopenia | 86.2 |
| Thrombocytopenia | 75.3 |
Chemical structure
| Molecular formula | — |
|---|---|
| Molecular weight | — |
| CAS number | — |
| InChIKey | — |
| PubChem CID | 72941969 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Imetelstat used for?
DrugCentral lists the following indications for Imetelstat: Low- to intermediate-1 risk myelodysplastic syndrome.
How does Imetelstat work?
Imetelstat is classified as Oligonucleotide Telomerase Inhibitors; its molecular targets in DrugCentral include TERT (inhibitor).
When was Imetelstat first approved?
Imetelstat was first approved by the FDA in 2024.
What drug class does Imetelstat belong to?
Imetelstat is in the Oligonucleotide Telomerase Inhibitor class.
Browse: all drugs starting with I · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 5823 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL2107856 — compound record and bioactivity
- PubChem CID 72941969 — chemical identifiers
- DrugBank DB05036 — drug record
- FDA UNII F60NE4XB53 — substance identity
- DailyMed: FDA labels for Imetelstat — current prescribing information (label search)
- UniProt O14746 (TERT) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.